Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Issue Information

Issue Information Worm et al. review recent developments in targeted cancer therapy. Peptide-binding G protein- coupled receptors (GPCRs) overexpressed in cancerous tissue can be addressed by peptide ligands, which in turn can serve as tumour- selective carriers for use in peptide- drug conjugates (PDCs). PDCs contain the peptide coupled to a smart linker that facilitates the controlled release of the attached drug. The drug can be a specific toxophore, radiolabel or boron-10 for boron neutron capture therapy. The receptor-PDC complex selectively binds to the cells that overexpress the targeted GPCR and is internalised, thus facilitating the drug to enter tumour cells while sparing healthy tissue. (doi: 10.1002/pep2.24171) EDITOR-IN-CHIEF P. Balaram William DeGrado Kit S. Lam Fred Naider Indian Institute of University of University of College of Staten Hilary J. Crichton Science California-San Francisco California-Davis Island Bangalore, India San Francisco, CA, Sacramento, CA, U.S.A. Staten Island, NY, U.S.A. ASSOCIATE EDITOR U.S.A. George Barany Yong-beom Lim Robin Offord Conor H. Doss University of Gregg B. Fields Yonsei University The Mintaka Minnesota Florida Atlantic Seoul, South Korea Foundation for Medical Minneapolis, MN, U.S.A. University Research EXECUTIVE EDITORS William D. Lubell Boca Raton, FL, U.S.A. Plan-les-Ouates, Annette G. Université de Montréal Joel P. Schneider Switzerland http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Peptide Science Wiley

Issue Information

Peptide Science , Volume 112 (3) – May 1, 2020
Download PDF
3 pages

Loading next page...
 
/lp/wiley/issue-information-P5ctNhVypl

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
© 2020 Wiley Periodicals, Inc.
eISSN
2475-8817
DOI
10.1002/pep2.24175
Publisher site
See Article on Publisher Site

Abstract

Worm et al. review recent developments in targeted cancer therapy. Peptide-binding G protein- coupled receptors (GPCRs) overexpressed in cancerous tissue can be addressed by peptide ligands, which in turn can serve as tumour- selective carriers for use in peptide- drug conjugates (PDCs). PDCs contain the peptide coupled to a smart linker that facilitates the controlled release of the attached drug. The drug can be a specific toxophore, radiolabel or boron-10 for boron neutron capture therapy. The receptor-PDC complex selectively binds to the cells that overexpress the targeted GPCR and is internalised, thus facilitating the drug to enter tumour cells while sparing healthy tissue. (doi: 10.1002/pep2.24171) EDITOR-IN-CHIEF P. Balaram William DeGrado Kit S. Lam Fred Naider Indian Institute of University of University of College of Staten Hilary J. Crichton Science California-San Francisco California-Davis Island Bangalore, India San Francisco, CA, Sacramento, CA, U.S.A. Staten Island, NY, U.S.A. ASSOCIATE EDITOR U.S.A. George Barany Yong-beom Lim Robin Offord Conor H. Doss University of Gregg B. Fields Yonsei University The Mintaka Minnesota Florida Atlantic Seoul, South Korea Foundation for Medical Minneapolis, MN, U.S.A. University Research EXECUTIVE EDITORS William D. Lubell Boca Raton, FL, U.S.A. Plan-les-Ouates, Annette G. Université de Montréal Joel P. Schneider Switzerland

Journal

Peptide Science – Wiley

Published: May 1, 2020

There are no references for this article.